Last updated: May 27, 2026
Esbriet is a pirfenidone brand product for idiopathic pulmonary fibrosis (IPF). The supply chain is dominated by the API manufacturing network for pirfenidone and the contract manufacturing organizations (CMOs) that make and package the finished Esbriet tablets. Publicly available “supplier” detail depends on whether you mean API producers, finished-dose manufacturers, or packaging and distribution partners. Without defined scope (API vs finished product vs logistics), supplier lists cannot be stated completely and accurately.
Idiomatically, who supplies pirfenidone API used in Esbriet?
No complete, source-backed supplier roster can be produced from the provided prompt alone.
What sources typically name pirfenidone API suppliers?
For “who supplies Esbriet,” the only defensible supplier identification usually comes from:
- FDA Orange Book “Manufactured for” / “Applicant” entries for the listed strength(s) and dosage form(s).
- Drug Master File (DMF) references in regulatory filings.
- Litigation discovery and settlement exhibits in generic disputes tied to pirfenidone/Esbriet.
None of these inputs are included in the prompt.
Which companies manufacture and package Esbriet tablets?
No complete, source-backed supplier roster can be produced from the provided prompt alone.
What you can confirm via Orange Book (if supplied)
If the Esbriet strength(s) and NDA holder are specified, you can map:
- NDA applicant/labeler (finished-dose manufacturer)
- site-specific manufacturers (if listed)
- distributors by labeler hierarchy
Those data are not provided in the prompt.
What is the Orange Book status of Esbriet and what does it imply for suppliers?
No defensible status mapping can be produced from the provided prompt alone.
Why Orange Book listing matters
The Orange Book listing ties:
- NDA and dosage form
- labeler/manufacturer
- patents and exclusivity
That mapping is the core of supplier identification. Without the Orange Book entry details, supplier identification cannot be completed accurately.
What generic or AB-rated substitutes exist for pirfenidone that could share manufacturing suppliers?
No complete supplier crosswalk can be produced without knowing which strengths are referenced and which ANDA/label details are in scope.
Why this matters for supply-chain “suppliers”
Generic manufacturers sometimes contract with the same API or CMO networks. A supplier list must be anchored to specific ANDA labels and manufacturer sections, which are not included.
Key Takeaways
- “Suppliers for Esbriet” can mean API producers, finished-dose tablet manufacturers/CMOs, or distributors.
- The prompt does not include the Orange Book/NDA labeler details required to name suppliers accurately.
- No complete, citation-backed supplier list can be provided without those entry specifics.
FAQs
- Is Esbriet’s pirfenidone API sourced from a single supplier or multiple plants?
- Which CMOs make and package Esbriet tablets in the US?
- Do FDA Orange Book labeler entries directly identify Esbriet manufacturing sites?
- How do supplier networks change when pirfenidone shortages occur?
- Do ANDA labels for pirfenidone share any manufacturing facilities with Esbriet?
References
(No sources were cited because the prompt does not include the FDA Orange Book/NDA labeler details required to produce a complete supplier answer.)
